Lupin Gains FDA Approval for Long-Acting Risperidone, Pioneering Injectable Innovation
Lupin Limited, a prominent international pharmaceutical company, declared that its Abbreviated New Drug Application (ANDA) for risperidone extended-release injectable suspension in 25 mg, 37.5 mg, and 50 mg per vial, intended for single-dose use, has been approved by the U.S….




























